BX E001
Alternative Names: BX-E001Latest Information Update: 28 Mar 2023
At a glance
- Originator Baylx
- Class Immunotherapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Colorectal-cancer(Late-stage disease) in USA (Parenteral)
- 14 Feb 2019 Preclinical trials in Colorectal cancer (Late-stage disease) in USA (Parenteral) before February 2019 (Baylx pipeline, February 2019)